Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32838299
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Addressing COVID-19 Drug Development with Artificial Intelligence
#MMPMID32838299
Ho D
Adv Intell Syst
2020[May]; 2
(5
): 2000070
PMID32838299
show ga
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that led to the COVID-19 (Coronavirus Disease 2019) pandemic, has
resulted in substantial overburdening of healthcare systems as well as an
economic crisis on a global scale. This has in turn resulted in widespread
efforts to identify suitable therapies to address this aggressive pathogen.
Therapeutic antibody and vaccine development are being actively explored, and a
phase I clinical trial of mRNA-1273 which is developed in collaboration between
the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is
currently underway. Timelines for the broad deployment of a vaccine and antibody
therapies have been estimated to be 12-18?months or longer. These are promising
approaches that may lead to sustained efficacy in treating COVID-19. However, its
emergence has also led to a large number of clinical trials evaluating drug
combinations composed of repurposed therapies. As study results of these
combinations continue to be evaluated, there is a need to move beyond traditional
drug screening and repurposing by harnessing artificial intelligence (AI) to
optimize combination therapy design. This may lead to the rapid identification of
regimens that mediate unexpected and markedly enhanced treatment outcomes.
free
free
free
